FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007156943> ?p ?o ?g. }

• W2007156943 endingPage "12" @default.
• W2007156943 startingPage "4" @default.
• W2007156943 abstract "Men with prostate cancer are at risk for bone loss and skeletal complications throughout the course of their disease. Bone loss is prevalent in many men with prostate cancer at initial diagnosis, and initiating androgen deprivation therapy results in accelerated bone resorption, leading to bone loss and an increased risk of fracture. These men are also at high risk for disease progression and bone metastases that can result in significant skeletal morbidity, including pathologic fracture, spinal cord compression, and debilitating bone pain requiring additional therapy. Excessive osteoclast activity plays a central role in the pathophysiology of bone disease at each stage of prostate cancer disease progression. Zoledronic acid, a highly potent inhibitor of osteoclast-mediated bone resorption, has increased bone mineral density in men receiving androgen deprivation therapy and is the only bisphosphonate that has shown statistically significant reductions in skeletal morbidity in patients with bone metastases from prostate cancer. Furthermore, preclinical evidence suggests that zoledronic acid has antitumor activity in prostate cancer models. Recently, a treatment algorithm was developed by the 3rd International Consultation on Prostate Cancer recommending the use of zoledronic acid for the prevention of skeletal complications in patients with bone metastases from prostate cancer, regardless of their hormone status, and for the prevention of treatment-induced bone loss in patients without evidence of bone metastases. According to this algorithm, zoledronic acid should be considered for the prevention of skeletal morbidity in patients with prostate cancer throughout their treatment continuum." @default.
• W2007156943 created "2016-06-24" @default.
• W2007156943 creator A5030594142 @default.
• W2007156943 creator A5053749991 @default.
• W2007156943 creator A5060409090 @default.
• W2007156943 date "2006-01-01" @default.
• W2007156943 modified "2023-10-13" @default.
• W2007156943 title "Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis" @default.
• W2007156943 cites W1485477721 @default.
• W2007156943 cites W165132104 @default.
• W2007156943 cites W1847691375 @default.
• W2007156943 cites W1865050205 @default.
• W2007156943 cites W1928668153 @default.
• W2007156943 cites W1932993947 @default.
• W2007156943 cites W1977951479 @default.
• W2007156943 cites W1990119475 @default.
• W2007156943 cites W1995807081 @default.
• W2007156943 cites W1996589664 @default.
• W2007156943 cites W2001372146 @default.
• W2007156943 cites W2009726500 @default.
• W2007156943 cites W2024266959 @default.
• W2007156943 cites W2027246239 @default.
• W2007156943 cites W2027735110 @default.
• W2007156943 cites W2031626307 @default.
• W2007156943 cites W2035837990 @default.
• W2007156943 cites W2040878961 @default.
• W2007156943 cites W2040906635 @default.
• W2007156943 cites W2058680827 @default.
• W2007156943 cites W2066969766 @default.
• W2007156943 cites W2073822933 @default.
• W2007156943 cites W2083492047 @default.
• W2007156943 cites W2084177425 @default.
• W2007156943 cites W2103314990 @default.
• W2007156943 cites W2104923745 @default.
• W2007156943 cites W2107208293 @default.
• W2007156943 cites W2110711752 @default.
• W2007156943 cites W2111758990 @default.
• W2007156943 cites W2115871403 @default.
• W2007156943 cites W2126048792 @default.
• W2007156943 cites W2136112016 @default.
• W2007156943 cites W2137083298 @default.
• W2007156943 cites W2161962336 @default.
• W2007156943 cites W2164859529 @default.
• W2007156943 cites W2167930119 @default.
• W2007156943 cites W2337912524 @default.
• W2007156943 cites W2435110265 @default.
• W2007156943 cites W2607028219 @default.
• W2007156943 cites W370919183 @default.
• W2007156943 cites W4297691666 @default.
• W2007156943 cites W2004111833 @default.
• W2007156943 doi "https://doi.org/10.1016/j.urolonc.2005.06.020" @default.
• W2007156943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16414486" @default.
• W2007156943 hasPublicationYear "2006" @default.
• W2007156943 type Work @default.
• W2007156943 sameAs 2007156943 @default.
• W2007156943 citedByCount "41" @default.
• W2007156943 countsByYear W20071569432012 @default.
• W2007156943 countsByYear W20071569432013 @default.
• W2007156943 countsByYear W20071569432014 @default.
• W2007156943 countsByYear W20071569432015 @default.
• W2007156943 countsByYear W20071569432016 @default.
• W2007156943 countsByYear W20071569432017 @default.
• W2007156943 countsByYear W20071569432018 @default.
• W2007156943 countsByYear W20071569432021 @default.
• W2007156943 countsByYear W20071569432022 @default.
• W2007156943 countsByYear W20071569432023 @default.
• W2007156943 crossrefType "journal-article" @default.
• W2007156943 hasAuthorship W2007156943A5030594142 @default.
• W2007156943 hasAuthorship W2007156943A5053749991 @default.
• W2007156943 hasAuthorship W2007156943A5060409090 @default.
• W2007156943 hasConcept C121608353 @default.
• W2007156943 hasConcept C126322002 @default.
• W2007156943 hasConcept C143998085 @default.
• W2007156943 hasConcept C170493617 @default.
• W2007156943 hasConcept C2776033226 @default.
• W2007156943 hasConcept C2776139714 @default.
• W2007156943 hasConcept C2776169692 @default.
• W2007156943 hasConcept C2776235491 @default.
• W2007156943 hasConcept C2776326535 @default.
• W2007156943 hasConcept C2776541429 @default.
• W2007156943 hasConcept C2776886416 @default.
• W2007156943 hasConcept C2777783956 @default.
• W2007156943 hasConcept C2777899217 @default.
• W2007156943 hasConcept C2780192828 @default.
• W2007156943 hasConcept C2911223091 @default.
• W2007156943 hasConcept C673006 @default.
• W2007156943 hasConcept C71924100 @default.
• W2007156943 hasConceptScore W2007156943C121608353 @default.
• W2007156943 hasConceptScore W2007156943C126322002 @default.
• W2007156943 hasConceptScore W2007156943C143998085 @default.
• W2007156943 hasConceptScore W2007156943C170493617 @default.
• W2007156943 hasConceptScore W2007156943C2776033226 @default.
• W2007156943 hasConceptScore W2007156943C2776139714 @default.
• W2007156943 hasConceptScore W2007156943C2776169692 @default.
• W2007156943 hasConceptScore W2007156943C2776235491 @default.
• W2007156943 hasConceptScore W2007156943C2776326535 @default.
• W2007156943 hasConceptScore W2007156943C2776541429 @default.
• W2007156943 hasConceptScore W2007156943C2776886416 @default.

• next